Odyssey Health, Inc. Forms Pharmaceutical Subsidiary Focused on Treating Neurological Diseases
11 oct. 2022 08h30 HE
|
Odyssey Health, Inc
Las Vegas, Nevada, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical...
Odyssey Health, Inc. Provides Recap on Concussion Drug Development
06 oct. 2022 08h30 HE
|
Odyssey Health, Inc
Las Vegas, Nevada, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical...
Global Biosensors Market Report 2022: Nanotechnology-Based Biosensors to Boost the Market Growth
05 oct. 2022 08h28 HE
|
Research and Markets
Dublin, Oct. 05, 2022 (GLOBE NEWSWIRE) -- The "Biosensors Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 To...
Odyssey Health, Inc. Makes Statement Regarding its Concussion Drug Development Program
30 sept. 2022 18h28 HE
|
Odyssey Health, Inc
Las Vegas Nevada, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., (the “Company” “Odyssey”) a company focused on developing a unique...
Odyssey Health, Inc. Announces Successful Completion of Phase I Clinical Trial for Concussion Drug
28 sept. 2022 08h30 HE
|
Odyssey Health, Inc
Las Vegas, Nevada, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical...
Cambridge Isotope Laboratories, Inc. (CIL) Partners With ISOtopic Solutions to Release the New Stable Isotope-Labeled and Unlabeled Crude Lipid Yeast Extracts
26 sept. 2022 15h16 HE
|
Cambridge Isotope Laboratories
TEWKSBURY, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Cambridge Isotope Laboratories, Inc. (CIL) has partnered with ISOtopic Solutions to release the new stable isotope-labeled and unlabeled Crude...
Sermonix Pharmaceuticals Announces Results of Phase 2 Study of Lasofoxifene vs. Fulvestrant in Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer and an ESR1 Mutation
13 sept. 2022 09h00 HE
|
Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated...
Japan Biotech Startups Directory 2022: Establishment, Technology, Patents, R&D Projects, Investors, Capital Policy, Management Team
05 sept. 2022 07h53 HE
|
Research and Markets
Dublin, Sept. 05, 2022 (GLOBE NEWSWIRE) -- The "The Directory of Biotech Startups in Japan 2021-2022" directory has been added to ResearchAndMarkets.com's offering. This report is a directory of...
Glycomics Global Market to Reach $3.22 Billion by 2028
02 sept. 2022 08h33 HE
|
Research and Markets
Dublin, Sept. 02, 2022 (GLOBE NEWSWIRE) -- The "Glycomics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product; Application; End User and Geography" report has been added to ...
Isracann Adds Super Bowl MVP and Mental Health Advocate Mark Rypien to Advisory Board
23 août 2022 09h00 HE
|
Isracann Biosciences Inc.
VANCOUVER, British Columbia, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) a multi-faceted organization with a natural health...